Core Viewpoint - Invivyd, Inc. will host a conference call on August 14, 2024, to discuss its Q2 financial results and recent business highlights [1]. Company Overview - Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2 [3]. - The company utilizes its proprietary INVYMAB™ platform, which integrates advanced viral surveillance, predictive modeling, and antibody engineering to rapidly generate new monoclonal antibodies (mAbs) [3]. - In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb, marking the beginning of a series of innovative antibody candidates [3].

Membership in the Russell 3000® Index means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as in the appropriate growth and value style indexes. The Russell 3000® Index encompasses the 3,000 largest U.S.-traded stocks by objective, market-capitalization rankings, and style attributes. Membership in these indexes is updated annually and remains in place for one year. For more information on the Russell 2000® and Russell 3000® Indexes and the Russell U.S. Ind ...

WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that as part of the annual reconstitution of the Russell stock indexes, Invivyd will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today. | --- | --- | |---------------------------------------------------------------------------------- ...

Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current dominant strains and the most recent FLiRT-containing viruses Invivyd's new data is broadly concordant with preliminary pseudovirus data showing neutralizing activity of VYD222 against KP.2 FLiRT and KP.3 variants recently publicized by an independent academic lab Invivyd's next anticipated SARS-CoV-2 monoclonal ...

WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET in New York, NY. In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the confer ...

WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET in New York, NY. In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the confer ...

Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and Amylyx Appointment intended to accelerate the addition of commercial capabilities associated with orphan medicines to the ongoing PEMGARDA™ commercial launch William Duke, Jr., Chief Financial Officer, appointed as Principal Executive Officer WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious ...

"Invivyd is off to an impressive start serving populations vulnerable to COVID-19. The company has a unique technology platform, industrial strategy and a commercial phase asset in PEMGARDA to show for their rapid and thoughtful approach to addressing the ongoing risk of COVID-19. COVID-19 represents intolerable medical risk for large immunocompromised and high-risk populations that, taken together, resemble very large orphan-style, highly motivated and vulnerable populations. Working together with the dedi ...

WALTHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will present preliminary, subset analyses from the CANOPY Phase 3 clinical trial of VYD222 (pemivibart) for pre-exposure prophylaxis of COVID-19 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and at the 2024 American Transplant Congress (ATC). The details for each meeting are as foll ...

Core Insights - Invivyd, Inc. has elected two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, to its Board of Directors during a period of significant growth for the company [1][2] - The company is focused on commercializing its first product and utilizing its proprietary tools for variant analysis and predictive modeling to develop advanced antibody candidates [2][6] - Invivyd has received emergency use authorization (EUA) from the U.S. FDA for its first monoclonal antibody (mAb) aimed at providing protection against COVID-19 for certain immunocompromised individuals [2][6] Company Overview - Invivyd, Inc. is a biopharmaceutical company dedicated to protecting against serious viral infectious diseases, starting with SARS-CoV-2 [6] - The company's INVYMAB™ platform integrates advanced viral surveillance and predictive modeling with antibody engineering to rapidly generate new mAbs [6] - The company aims to provide ongoing protection to vulnerable populations against evolving viral threats [2][6] New Board Members - Dr. Srishti Gupta brings over 20 years of healthcare experience, including 18 years at McKinsey & Company, and currently serves on the Board of Directors at Idorsia Pharmaceuticals [3] - Kevin F. McLaughlin has over 40 years of financial and operational management experience, previously serving as CFO of Acceleron Pharma, and currently holds positions on several other boards [4][5] Strategic Importance - The addition of Dr. Gupta and Mr. McLaughlin is seen as crucial for Invivyd as it transitions into a commercial organization and seeks to leverage its innovative platform for future growth [2][3][4] - The company is positioned to address the ongoing challenges posed by COVID-19, particularly for immunocompromised populations, through its mAb candidates [2][6]